| 臺大學術典藏 |
2020-12-02T02:34:19Z |
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
|
Tan E.-H.;Ramlau R.;Pluzanska A.;Kuo H.-P.;Reck M.;Milanowski J.;Au J.S.-K.;Felip E.;Pan-Chyr Yang;Damyanov D.;Orlov S.;Akimov M.;Delmar P.;Essioux L.;Hillenbach C.;Klughammer B.;Mcloughlin P.;Baselga J.; Tan E.-H.; Ramlau R.; Pluzanska A.; Kuo H.-P.; Reck M.; Milanowski J.; Au J.S.-K.; Felip E.; PAN-CHYR YANG; Damyanov D.; Orlov S.; Akimov M.; Delmar P.; Essioux L.; Hillenbach C.; Klughammer B.; McLoughlin P.; Baselga J. |
| 臺大學術典藏 |
2020-05-25T07:35:15Z |
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
|
Reynolds K.L; Bedard P.L; Lee S.-H; Chia-Chi Lin; Tabernero J; Alsina M; Cohen E; Baselga J; Blumenschein G; Graham D.M; Garrido-Laguna I; Juric D; Sharma S; Salgia R; Seroutou A; Tian X; Fernandez R; Morozov A; Sheng Q; Ramkumar T; Zubel A; Bang Y.-J. |
| 臺大學術典藏 |
2016 |
Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results From the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial
|
Piccart-Gebhart M.; Holmes E.; Baselga J.; De Azambuja E.; Dueck A.C.; Viale G.; Zujewski J.A.; Goldhirsch A.; Armour A.; Pritchard K.I.; McCullough A.E.; Dolci S.; McFadden E.; Holmes A.P.; Tonghua L.; Im Y.-H.; CHIUN-SHENG HUANG; D?eras V.; Hillman D.W.; Wolff A.C.; Jackisch C.; Lang I.; Untch M.; Smith I.; Boyle F.; Xu B.; Gomez H.; Suter T.; Gelber R.D.; Perez E.A.; Eidtmann H.; Dinh P.; Di Cosimo S.; Harbeck N.; Tjulandin S. |
| 臺大學術典藏 |
2020-03-23T07:18:54Z |
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))
|
Shao Z.; Semiglazov V.; Rutgers E.J.T.; Sedlmayer F.; Ro J.; Pritchard K.; Partridge A.H.; Pagani O.; Osborne K.C.; Orecchia R.; Morrow M.; Karlsson P.; Jiang Z.; Jassem J.; Curigliano G.;Burstein H.J.;Winer E.P.;Gnant M.;Dubsky P.;Loibl S.;Colleoni M.;Regan M.M.;Piccart-Gebhart M.;Senn H.-J.;Th?Rlimann B.;Andr? F.;Baselga J.;Bergh J.;Bonnefoi H.;Brucker S.Y.;Cardoso F.;Carey L.;Ciruelos E.;Cuzick J.;Denkert C.;Di Leo A.;Ejlertsen B.;Francis P.;Galimberti V.;Garber J.;Gulluoglu B.;Goodwin P.;Harbeck N.;Hayes D.F.;Chiun-Sheng Huang;Huober J.;Khaled H.;Jassem J.;Jiang Z.;Karlsson P.;Morrow M.;Orecchia R.;Osborne K.C.;Pagani O.;Partridge A.H.;Pritchard K.;Ro J.;Rutgers E.J.T.;Sedlmayer F.;Semiglazov V.;Shao Z.;Smith I.;Toi M.;Tutt A.;Viale G.;Watanabe T.;Whelan T.J.;Xu B.; Curigliano G.; Burstein H.J.; Winer E.P.; Gnant M.; Dubsky P.; Loibl S.; Colleoni M.; Regan M.M.; Piccart-Gebhart M.; Senn H.-J.; Th?rlimann B.; Andr? F.; Baselga J.; Bergh J.; Bonnefoi H.; Brucker S.Y.; Cardoso F.; Carey L.; Ciruelos E.; Cuzick J.; Denkert C.; Di Leo A.; Ejlertsen B.; Francis P.; Galimberti V.; Garber J.; Gulluoglu B.; Goodwin P.; Harbeck N.; Hayes D.F.; CHIUN-SHENG HUANG; Huober J.; Khaled H.; Smith I.; Toi M.; Tutt A.; Viale G.; Watanabe T.; Whelan T.J.; Xu B. |
| 臺大學術典藏 |
2020-03-23T07:18:59Z |
De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|
Smith I.; Toi M.; Tutt A.; Viale G.; Watanabe T.; Whelan T.J.; Xu B.; Galimberti V.; Francis P.; Ejlertsen B.; Denkert C.; Di Leo A.; Cuzick J.; Loibl S.; Colleoni M.; M. Regan M.; Piccart-Gebhart M.; Senn H.-J.; Th?rlimann B.; Andr? F.; Baselga J.; Bergh J.; Bonnefoi H.; Brucker S.Y.; Cardoso F.; Carey L.; Ciruelos E.; Shao Z.; Semiglazov V.; Rutgers E.J.T.; Sedlmayer F.; Ro J.; Pritchard K.; Partridge A.H.; Garber J.; Gulluoglu B.; Goodwin P.; Harbeck N.; F. Hayes D.; CHIUN-SHENG HUANG; Huober J.; Hussein K.; Jassem J.; Jiang Z.; Karlsson P.; Morrow M.; Orecchia R.; Osborne K.C.; Pagani O.; Dubsky P.; Gnant M.; Winer E.P.; Burstein H.J.; Curigliano G.; Curigliano G.;Burstein H.J.;Winer E.P.;Gnant M.;Dubsky P.;Loibl S.;Colleoni M.;M. Regan M.;Piccart-Gebhart M.;Senn H.-J.;Th?Rlimann B.;Andr? F.;Baselga J.;Bergh J.;Bonnefoi H.;Brucker S.Y.;Cardoso F.;Carey L.;Ciruelos E.;Cuzick J.;Denkert C.;Di Leo A.;Ejlertsen B.;Francis P.;Galimberti V.;Garber J.;Gulluoglu B.;Goodwin P.;Harbeck N.;F. Hayes D.;Chiun-Sheng Huang;Huober J.;Hussein K.;Jassem J.;Jiang Z.;Karlsson P.;Morrow M.;Orecchia R.;Osborne K.C.;Pagani O.;Partridge A.H.;Pritchard K.;Ro J.;Rutgers E.J.T.;Sedlmayer F.;Semiglazov V.;Shao Z.;Smith I.;Toi M.;Tutt A.;Viale G.;Watanabe T.;Whelan T.J.;Xu B. |
| 國立成功大學 |
2015-09 |
Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial
|
Sotiriou, C.; Venet, D.; Fumagalli, D.; Maetens, M.; Rothe, F.; Ignatiadis, M.; Bradbury, I.; Harbeck, N.; Gomez, H.; Chang, T. W.; Coccia-Portugal, M. A.; Di Cosimo, S.; De Azambuja, E.; De la Pena, L.; Nuciforo, P.; Armour, A.; Eidtmann, H.; Baselga, J.; Piccart, M.; Loi, S. |
| 臺大學術典藏 |
2017 |
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
|
Kim S.-B.;Maslyar D.J.;Dent R.;Im S.-A.;Espi? M.;Blau S.;Tan A.R.;Isakoff S.J.;Oliveira M.;Saura C.;Wongchenko M.J.;Kapp A.V.;Chan W.Y.;Singel S.M.;Baselga J.;Kim S.-B.;Lee K.S.;Im S.-A.;Espi? M.;Wang H.-C.;Blau S.;Dent R.;Tan A.;Sohn J.H.;De Laurentiis M.;Estevez L.G.;Chiun-Sheng Huang;Romieu G.;Velez M.;Villanueva R.;Conte P.F.;Dakhil S.;Debled M.;Martin A.G.;Hurvitz S.;Kim J.H.;Levy C.;Oliveira M.;Rovira P.S.;Seo J.H.;Valero V.;Vidal G.;Wong A.;Allison M.A.K.;Figlin R.;Chan D.;Chen S.-C.;Chen Y.-H.;Cobleigh M.;De Braud F.;Dirix L.;Hansen V.;Bessard A.H.;Iannotti N.;Isakoff S.;Lawler W.;Monta?O A.;Salkini M.;Seigel L.;On Behalf Of The, Lotus Investigators, Lotus Investigators; Estevez L.G.; De Laurentiis M.; Sohn J.H.; Wang H.-C.; Blau S.; Dent R.; Tan A.; Espi? M.; Im S.-A.; Lee K.S.; Kim S.-B.; Baselga J.; Kim S.-B.; Maslyar D.J.; Dent R.; Im S.-A.; Espi? M.; Blau S.; Tan A.R.; Isakoff S.J.; Oliveira M.; Saura C.; Wongchenko M.J.; Kapp A.V.; Chan W.Y.; Singel S.M.; Allison M.A.K.; Vidal G.; Wong A.; Valero V.; Seo J.H.; CHIUN-SHENG HUANG; Romieu G.; Velez M.; Villanueva R.; Conte P.F.; Dakhil S.; Debled M.; Martin A.G.; Hurvitz S.; Kim J.H.; Levy C.; Oliveira M.; Rovira P.S.; on behalf of the, LOTUS investigators, LOTUS investigators; Seigel L.; Salkini M.; Monta?o A.; Figlin R.; Chan D.; Chen S.-C.; Chen Y.-H.; Cobleigh M.; De Braud F.; Dirix L.; Hansen V.; Bessard A.H.; Iannotti N.; Isakoff S.; Lawler W. |
| 臺大學術典藏 |
2020-03-23T07:19:13Z |
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
|
Xu B.; Boyle F.; Smith I.; Jackisch C.; Lang I.; Untch M.; Swaby R.F.; Di Cosimo S.; Holmes E.; Piccart-Gebhart M.; Holmes A.P.; De Azambuja E.;Holmes A.P.;Piccart-Gebhart M.;Holmes E.;Di Cosimo S.;Swaby R.F.;Untch M.;Jackisch C.;Lang I.;Smith I.;Boyle F.;Xu B.;Barrios C.H.;Perez E.A.;Azim H.A.;Kim S.-B.;Kuemmel S.;Chiun-Sheng Huang;Vuylsteke P.;Hsieh R.-K.;Gorbunova V.;Eniu A.;Dreosti L.;Tavartkiladze N.;Gelber R.D.;Eidtmann H.;Baselga J.; De Azambuja E.; Barrios C.H.; Perez E.A.; Azim H.A.; Kim S.-B.; Kuemmel S.; CHIUN-SHENG HUANG; Vuylsteke P.; Hsieh R.-K.; Gorbunova V.; Eniu A.; Dreosti L.; Tavartkiladze N.; Gelber R.D.; Eidtmann H.; Baselga J. |
| 臺大學術典藏 |
2020-03-23T07:18:53Z |
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial
|
Bardia A.; Bardia A.;Parton M.;Kummel S.;Estevez L.G.;Chiun-Sheng Huang;Cortes J.;Ruiz-Borrego M.;Telli M.L.;Martin-Martorell P.;Lopez R.;Beck J.T.;Ismail-Khan R.;Chen S.-C.;Hurvitz S.A.;Mayer I.A.;Carreon D.;Cameron S.;Liao S.;Baselga J.;Kim S.-B.; Parton M.; Kummel S.; Estevez L.G.; CHIUN-SHENG HUANG; Cortes J.; Ruiz-Borrego M.; Telli M.L.; Martin-Martorell P.; Lopez R.; Beck J.T.; Ismail-Khan R.; Chen S.-C.; Hurvitz S.A.; Mayer I.A.; Carreon D.; Cameron S.; Liao S.; Baselga J.; Kim S.-B. |
| 臺大學術典藏 |
2018-09-10T09:52:25Z |
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: Analysis from the NeoALTTO trial
|
Agbor-Tarh, D.; Bradbury, I.; Dinh, P.; Baselga, J.; Di Cosimo, S.; Greger Jr.; J.G.; Smith, I.; Jackisch, C.; Kim, S.-B.; Aktas, B.; Huang, C.-S.; Vuylsteke, P.; Hsieh, R.K.; Dreosti, L.; Eidtmann, H.; Piccart, M.; De Azambuja, E.; CHIUN-SHENG HUANG |
